Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

ABSTRACT: Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

PROVIDER: PRJNA475565 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7290240_1.fastq.gz	Fastqsanger.gz
	SRR7290240_2.fastq.gz	Fastqsanger.gz
	SRR7290250_1.fastq.gz	Fastqsanger.gz
	SRR7290250_2.fastq.gz	Fastqsanger.gz
	SRR7290260_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 52

Similar Datasets

Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

Project description:The objective of this experiment was to determine the affect of H3B-5942 treatment on global gene expression in an estrogen-deprived setting (agonist mode) and to compare to treatment with a saturated analog of H3B-5942, GDC-0810, and standard of care agents tamoxifen and fulvestrant.

2018-06-12 | GSE115608 | GEO

Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds

Project description:The objective of this experiment was to compare the affect of H3B-5942 treatment on global gene expression and to compare to treatment with standard of care agents tamoxifen and fulvestrant.

2018-06-12 | GSE115609 | GEO

ChIP-Seq analysis of estrogen deprived MCF7 cells treated with H3B-5942 and standards of care compounds

Project description:The goal of this experiment was to interrogate the potential transcriptional impact of H3B-5942 by investigating its influence on genome-wide DNA-binding modes of ERa in MCF7 cells using chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-Seq). Affects of H3B-5942 on chromatin recruitment were compared to results from treatment with E2, 4-OHT, and fulvestrant.

2018-06-12 | GSE115607 | GEO

Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds

Project description:Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds

| PRJNA475566 | ENA

Expression data from the study of the oestrognic activity of glabridin in Ishikawa cells in comparison to 17β-oestradiol (17β-E2)

Project description:The general objective of this study was to investigate the effects of glabridin in Ishikawa cells in comparison to 17β-oestradiol by studying its mechanism of action via Affymetrix GeneChip® PrimeViewTM array The treatments were the unctreated control, 10µM glabridin, 100nM glabridin, 1nM 17β-E2 and the combination treatment of 1nM 17β-E2 with 100nM glabridin. The cells were treated for 72 hours and the RNA were extracted for microarray and RT-qPCR study.

2015-04-29 | E-GEOD-68333 | biostudies-arrayexpress

Gene expression regulation in MCF7 cells by H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

Project description:In the cellular setting, both H3B-6545 and H3B-9709 were confirmed to be non-degraders and had nearly identical impact on global gene expression changes

2022-03-15 | GSE178303 | GEO

ChIP-Seq analysis of estrogen deprived MCF7 cells treated with H3B-5942 and standards of care compounds

Project description:ChIP-Seq analysis of estrogen deprived MCF7 cells treated with H3B-5942 and standards of care compounds

| PRJNA475564 | ENA

Analysis of gene expression change between Ishikawa-02 SC and Ishikawa-02 shSOX2

Project description:We collected total RNA from both Ishikawa-02 SC and Ishikawa-02 shSOX2 and examined mRNA expression profile, comprehensively.

2018-05-18 | GSE114582 | GEO

Effects of Estrogen and Tamoxifen on Ishikawa cells after 24h and 48h

Project description:Treatment with the breast cancer drug tamoxifen confers a risk of developing uterine tumors or other endometrial pathologies. Tamoxifen is a selective estrogen receptor modulator, which demonstrates tissue-specific activity although the mechanisms remain poorly understood. Both estradiol and tamoxifen act as estrogen agonists on the human uterus, and therefore have the potential to promote carcinogenicity. Estradiol and tamoxifen elicit cellular responses via the estrogen receptors (ER), which are involved in multiple signalling pathways. The effects at the molecular level are further influenced by the differential recruitment of co-factors and the presence of specific promoter motifs in target genes. In this study, ER positive (+) Ishikawa cells are used as a model to investigate the overall effect of treatment with either 17b-estradiol or 4-hydroxytamoxifen on the gene expression profiles. Ishikawa cells were serum-starved for 72 hours prior to treatment with 10-8M 17b-estradiol (E2) or 10-6M 4-hydroxytamoxifen (tam) for 24 or 48 hours. Cells were collected for total RNA extraction, and the quality and quantity of the RNA was determined spectrophotometrically. cDNA was prepared from treated (tam or E2) and control (vehicle only) Ishikawa cells, and was both forward and reverse labelled using Cy-3 dUTP/ Cy-5 dUTP and hybridised to oligo microarray slides representing >19,000 human genes (MRC HGMP-RFC). The data were analysed using GenePix Pro 3.0 software (Axon instruments) and statistical analyses applied to select significant gene changes (p<0.05).

2010-07-01 | E-GEOD-3762 | biostudies-arrayexpress

RNA-Seq of human cell lines Ishikawa, MCF7 and T47D treated with estrogen, progesterone and their antagonists

Project description:In this study the effect of estrogen (E2) and progesterone (P4) and their antagonists Tamoxifen, and Mifepristone (RU486) were assesed in endometrial epithelial cell line Ishikawa and compared to breast cancer cell lines MCF7 and T47D. Concentrations used for E2 and P4 treatments were 10 -8 M and for antagonists 10 -6 M. RNA-Sequencing (Illumina GenomeAnalyzer IIe) was applied to study global gene expression in three different cell lines. Expression values after hormonal or antagonist treatments in two different time points (3h and 12h) were compared to non-treated cells.

2012-01-05 | E-MTAB-822 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data